FDA Issues Letter of Support for Biomarker to Detect Neurodegenerative Disorders

The FDA issued a Letter of Support to the Critical Path Institute’s Parkinson’s consortium to encourage the use of alpha-synuclein (α-syn) — a pathologic protein linked to several neurodegenerative diseases — as a biomarker to identify people at risk of developing Parkinson’s disease and related syndromes.
Source: Drug Industry Daily